Colon/Rectal Clinical Trials

From DolceraWiki
Revision as of 22:06, 6 October 2011 by Sonal.pingle (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

To go back to the main page, click here

S.No Drug Name Biological Name Developer Current Development Phase Additional Information Start Date Completion Date Source
11 - carcinoembryonic antigen RNA-pulsed DC cancer vaccine Duke University, National Cancer Institute (NCI) I Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic cancer that has not responded to previous treatment. 2000 2009 Source
12 - carcinoembryonic antigen RNA-pulsed DC cancer vaccine Duke University, National Cancer Institute (NCI) I/II Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with resected liver metastases from colon cancer. 1999 2009 Source
13 - QS21, ras peptide cancer vaccine Fox Chase Cancer Center, National Cancer Institute (NCI) I Phase I trial to study the effectiveness of vaccine therapy plus QS21 in treating patients who have advanced pancreatic or colorectal cancer. - - Source
14 GI-4000 - GlobeImmune II The purpose of this study is to test the safety of GI-4000 and see what effects (good and bad) it has against cancer over time 2010 2013 Source
15 - Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated Hadassah Medical Organization I/II This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with colorectal, gastric, ovarian, breast or lung epithelial cancer - - Source
16 Endoxana, Leukine, IMA910, Aldara - Immatics Biotechnologies GmbH I/II This study is being conducted in order determine whether IMA910 as single agent with GM-CSF as adjuvant following pre-treatment with low-dose cyclophosphamide is safe and shows sufficient anti-tumour effectiveness in patients with advanced CRC to warrant further development 2008 2012 Source
17 - PSMA/PRAME MannKind Corporation I Completed
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.
2007 2009 Source
18 MEDI-547 - MedImmune/Anza I Terminated.
Purpose was: To determine the safety, tolerability, and the highest dose of this drug given once every 3 weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory solid tumors
2009 2010 Source
19 - V930 /V932 Merck I Completed.
Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens
2007 2009 Source
20 - V934/V935 Merck I Completed.
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
2008 2011 Source
21 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
22 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
23 - Interleukin-2 National Cancer Institute (NCI) II Phase II trial to study the effectiveness of a vaccine made with the patients white blood cells mixed with tumor proteins in treating patients who have advanced cancer. - - -
24 - Aldesleukin, ras peptide cancer vaccine National Cancer Institute (NCI) I/II Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have locally advanced or metastatic colorectal cancer. 1999 Ongoing Source
25 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
26 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
27 - ONT-10 Oncothyreon Preclinical - - - -
28 Interferon-alpha Trovax Oxford BioMedica II Study has been completed 2006 2008 Source
29 - AdhTAP TapImmune Preclinical - - - -
30 - OncoVAX autologous
vaccine
Vaccinogen III Available in Netherlands/Switzerland Possible U.S. and E.U. approvals in 2014 - - -
31 - CEA DNA Cancer
Vaccine
Vical/Merck I The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers. 2007 2009 -




To go back to the main page, click here